Profile data is unavailable for this security.
About the company
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
- Revenue in USD (TTM)31.47m
- Net income in USD-140.49m
- Incorporated2003
- Employees165.00
- LocationMarinus Pharmaceuticals Inc5 Radnor Corporate Center Suite 500100 Matsonford RdRADNOR 19087United StatesUSA
- Phone+1 (484) 801-4670
- Fax+1 (302) 655-5049
- Websitehttps://marinuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Essence Corp | 593.21k | -1.02m | 9.88m | 12.00 | -- | -- | -- | 16.66 | -0.0278 | -0.0156 | 0.0158 | -0.0458 | 0.3305 | -- | 21.20 | -- | -57.09 | -46.10 | -- | -- | 25.05 | 33.89 | -172.74 | -111.21 | -- | -59.99 | 7.03 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| Immunoprecise Antibodies Ltd | 17.25m | -19.76m | 10.05m | 102.00 | -- | 0.4045 | -- | 0.5825 | -0.7468 | -0.7468 | 0.6593 | 0.8614 | 0.3546 | 6.12 | 6.16 | -- | -40.63 | -26.70 | -46.68 | -30.31 | 48.21 | 56.13 | -114.58 | -85.72 | 0.8189 | -134.72 | 0.3289 | -- | 18.65 | 17.54 | -2.32 | -- | 16.71 | -- |
| Talphera Inc | 281.00k | -15.64m | 11.88m | 15.00 | -- | 1.23 | -- | 42.28 | -0.6786 | -0.6792 | 0.0118 | 0.5662 | 0.0127 | -- | -- | 18,733.33 | -70.64 | -22.60 | -82.44 | -28.55 | -- | -- | -5,565.48 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Gelteq Ltd | 0.00 | -1.54m | 14.82m | -- | -- | 1.05 | -- | -- | -0.1611 | -0.1611 | 0.00 | 1.50 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 36.79m | -10.87m | 15.17m | 91.00 | -- | 0.6107 | -- | 0.4123 | -0.7692 | -0.7692 | 2.61 | 1.77 | 0.4472 | 0.9316 | 3.07 | 404,235.70 | -13.18 | -7.03 | -20.32 | -9.52 | 83.31 | 79.95 | -29.48 | -17.64 | 0.9884 | -29.44 | 0.3967 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Bright Green Corp | 0.00 | -9.03m | 15.33m | 5.00 | -- | 1.71 | -- | -- | -0.0485 | -0.0485 | 0.00 | 0.0467 | 0.00 | -- | -- | 0.00 | -44.63 | -- | -73.32 | -- | -- | -- | -- | -- | -- | -13,031.30 | 0.0828 | -- | -- | -- | 52.54 | -- | -- | -- |
| TherapeuticsMD Inc | 1.60m | -3.97m | 15.34m | 1.00 | -- | 0.5661 | -- | 9.61 | -0.3499 | -0.291 | 0.1399 | 2.35 | 0.0355 | -- | 0.4944 | 1,596,000.00 | -8.81 | -53.35 | -11.41 | -111.61 | 31.45 | 86.67 | -248.56 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cara Therapeutics Inc | 8.69m | -95.53m | 17.01m | 55.00 | -- | 24.05 | -- | 1.96 | -1.75 | -1.75 | 0.1589 | 0.0129 | 0.1042 | 0.6312 | 4.59 | 157,927.30 | -114.63 | -35.76 | -142.84 | -40.82 | 56.44 | -- | -1,099.76 | -162.10 | 4.71 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Marinus Pharmaceuticals Inc | 31.47m | -140.49m | 17.75m | 165.00 | -- | -- | -- | 0.5642 | -2.47 | -2.47 | 0.5524 | -1.21 | 0.238 | 0.6542 | 7.75 | 190,703.00 | -106.26 | -49.64 | -140.93 | -57.76 | 90.17 | -- | -446.49 | -518.96 | 1.47 | -10.06 | -- | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 19.54m | 1.00 | -- | -- | -- | 195,396.80 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cyclo Therapeutics Inc | 870.72k | -24.80m | 20.06m | 8.00 | -- | -- | -- | 23.04 | -0.9232 | -0.9232 | 0.0322 | -0.4683 | 0.1605 | 0.342 | 3.54 | 108,840.00 | -457.10 | -132.22 | -- | -215.17 | 91.24 | 90.37 | -2,848.18 | -1,114.04 | 0.1614 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Nexgel Inc | 6.73m | -3.53m | 22.13m | 19.00 | -- | 4.74 | -- | 3.29 | -0.5815 | -0.5815 | 1.10 | 0.6902 | 0.6558 | 3.21 | 6.56 | 354,105.30 | -37.28 | -44.61 | -51.10 | -56.19 | 31.61 | 5.02 | -56.85 | -180.98 | 0.9291 | -- | 0.2235 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| BioXcel Therapeutics Inc | 2.28m | -71.00m | 23.25m | 74.00 | -- | -- | -- | 10.21 | -2.15 | -2.15 | 0.0637 | -2.02 | 0.0305 | 1.14 | 6.17 | 30,756.76 | -95.08 | -74.57 | -168.28 | -84.06 | 10.98 | -- | -3,119.33 | -32,300.74 | 1.81 | -6.54 | 5.55 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Polypid Ltd | 0.00 | -26.86m | 23.34m | 59.00 | -- | 10.81 | -- | -- | -7.48 | -7.48 | 0.00 | 0.3172 | 0.00 | -- | -- | 0.00 | -132.55 | -76.92 | -222.42 | -89.61 | -- | -- | -- | -- | -- | -25.48 | 0.7813 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
Data as of Nov 22 2024. Currency figures normalised to Marinus Pharmaceuticals Inc's reporting currency: US Dollar USD
47.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 30 Sep 2024 | 5.07m | 9.21% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 4.71m | 8.56% |
| Tang Capital Management LLCas of 30 Sep 2024 | 4.70m | 8.53% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.78m | 5.06% |
| abrdn, Inc.as of 30 Sep 2024 | 2.66m | 4.83% |
| Bleichroeder LPas of 30 Sep 2024 | 1.87m | 3.40% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.36m | 2.46% |
| Woodline Partners LPas of 30 Sep 2024 | 1.26m | 2.30% |
| GSA Capital Partners LLPas of 30 Sep 2024 | 1.02m | 1.85% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 910.34k | 1.65% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
